ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.12 and traded as low as $0.1740. ProPhase Labs shares last traded at $0.1998, with a volume of 490,748 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ProPhase Labs in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, ProPhase Labs currently has a consensus rating of “Sell”.

ProPhase Labs Trading Up 8.0%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The stock has a 50-day simple moving average of $1.39 and a two-hundred day simple moving average of $3.12. The firm has a market cap of $1.20 million, a PE ratio of -0.05 and a beta of -0.56.

ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Wednesday, November 19th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.50). The company had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $5.69 million. ProPhase Labs had a negative return on equity of 482.05% and a negative net margin of 825.01%. As a group, sell-side analysts anticipate that ProPhase Labs, Inc. will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PRPH. Sykon Capital LLC bought a new position in ProPhase Labs in the 2nd quarter worth $252,000. Susquehanna International Group LLP lifted its position in shares of ProPhase Labs by 290.1% in the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after buying an additional 295,899 shares in the last quarter. Accretive Wealth Partners LLC purchased a new stake in shares of ProPhase Labs during the 3rd quarter worth approximately $114,000. Apollon Wealth Management LLC bought a new position in ProPhase Labs during the third quarter valued at $84,000. Finally, XTX Topco Ltd bought a new position in shares of ProPhase Labs in the 2nd quarter valued at about $40,000. 9.45% of the stock is currently owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.